Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polymyxin B-based combination therapy for CRPA infection in hematological malignancies
ChiCTR2100049105Phase 4Not yet recruiting
- Sponsor
- Zhejiang Hospital of Traditional Chinese Medicine
- Start
- Aug 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polymyxin B in Pseudomonal infection and hematopoietic malignancies, sponsored by Zhejiang Hospital of Traditional Chinese Medicine. Primary endpoint: Treatment success rate. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
polymyxin B
03
Conditions
Pseudomonal infectionhematopoietic malignancies
Beyond the preview
Go deeper on ChiCTR2100049105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049105.